Sponsor
Shanghai JMT-Bio Inc.
Clinical research sponsor
Clinical trials
18 shownA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460 · lead sponsor · 2026-03-06
RECRUITINGJMT106 Injection in the Treatment of Advanced Solid TumorsNCT07275073 · lead sponsor · 2025-09-25
RECRUITINGA Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsNCT06829459 · lead sponsor · 2025-04-03
RECRUITINGJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerNCT06846437 · lead sponsor · 2025-02-18
RECRUITINGA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsNCT06735391 · lead sponsor · 2024-10-23
RECRUITINGA Study of JMT203 in Patients With Cancer CachexiaNCT06868849 · lead sponsor · 2024-05-15
RECRUITINGEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.NCT05838066 · lead sponsor · 2023-07-23
RECRUITINGEvaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsNCT07840729 · lead sponsor · 2026-10-20
NOT_YET_RECRUITINGA Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNCT07545044 · lead sponsor · 2026-05-30
NOT_YET_RECRUITINGSYS6090 Combination Therapy in Advanced Lung CancerNCT07472647 · lead sponsor · 2026-02-28
NOT_YET_RECRUITINGGlumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNCT06908772 · lead sponsor · 2025-04-01
NOT_YET_RECRUITINGA Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerNCT06747338 · lead sponsor · 2024-12-16
ACTIVE_NOT_RECRUITINGEfficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerNCT06319313 · lead sponsor · 2024-05-01
NOT_YET_RECRUITINGJMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNCT06380348 · lead sponsor · 2024-04-26
NOT_YET_RECRUITINGReal-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerNCT05513664 · lead sponsor · 2022-09-01
UNKNOWNJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsNCT06391944 · lead sponsor · 2021-11-21
ACTIVE_NOT_RECRUITINGEfficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerNCT05132777 · lead sponsor · 2021-11-20
UNKNOWNEfficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerNCT04448379 · lead sponsor · 2020-06-29
UNKNOWNSponsor roles
lead sponsor18
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.